A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

January 31, 2014

Conditions
Endometrial Carcinoma
Interventions
DRUG

GDC-0980

Oral daily dose

Trial Locations (28)

10016

New York

10017

New York

15213

Pittsburgh

19001

Abington

21231

Baltimore

27103

Winston-Salem

27710

Durham

32804

Orlando

33401

West Palm Beach

33487

Boca Raton

40202

Louisville

46237

Indianapolis

53226

Milwaukee

60521

Hinsdale

73104

Oklahoma City

80220

Denver

84112

Salt Lake City

85013

Phoenix

92663

Newport Beach

92868

Orange

94115

San Francisco

94305

Palo Alto

98195

Seattle

06511

New Haven

04074

Scarborough

02115-6084

Boston

02215

Boston

08043

Voorhees Township

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY